1 Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies 2 to SARS-CoV-2 Douglas F. Lake^{1*#}, Alexa J. Roeder^{1*}, Erin Kaleta², Paniz Jasbi³, Kirsten Pfeffer¹, 3 Calvin Koelbel¹ Sivakumar Periasamy^{4,5} Natalia Kuzmina^{4,5} Alexander Bukreyev^{4,5,6}, 4 Thomas E. Grys², Liang Wu⁷, John R Mills⁷, Kathrine McAulay², Maria Gonzalez-Moa⁸, 5 Alim Seit-Nebi⁸, and Sergei Svarovsky⁸ 6 7 8 Affiliations: 9 1. School of Life Sciences, Arizona State University, Tempe AZ, USA 10 2. Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, 11 Scottsdale, AZ, USA 12 3. College of Health Solutions, Arizona State University, Phoenix AZ, USA 4. Department of Pathology, University of Texas Medical Branch at Galveston, 13 14 Galveston, TX USA 15 5. Galveston National Laboratory, University of Texas Medical Branch at Galveston, 16 Galveston, TX USA 17 6. Department of Microbiology and Immunology University of Texas Medical Branch at Galveston, Galveston, TX USA 18 19 7. Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, 20 Rochester, MN USA 21 8. Axim Biotechnologies Inc, San Diego, CA USA *Co-first authors 22 23 #Address correspondence to Douglas F. Lake, douglas.lake@asu.edu 24 25 Word Count: 2498 26 27

28 Abstract:

Background: After receiving a COVID-19 vaccine, most recipients want to know if they 29 30 are protected from infection and for how long. Since neutralizing antibodies are a 31 correlate of protection, we developed a lateral flow assay (LFA) that measures levels of 32 neutralizing antibodies from a drop of blood. The LFA is based on the principle that 33 neutralizing antibodies block binding of the receptor-binding domain (RBD) to 34 angiotensin-converting enzyme 2 (ACE2). 35 Methods: The ability of the LFA was assessed to correctly measure neutralization of 36 sera, plasma or whole blood from patients with COVID-19 using SARS-CoV-2 37 microneutralization assays. We also determined if the LFA distinguished patients with 38 seasonal respiratory viruses from patients with COVID-19. To demonstrate the 39 usefulness of the LFA, we tested previously infected and non-infected COVID-19 40 vaccine recipients at baseline and after first and second vaccine doses. 41 **Results:** The LFA compared favorably with SARS-CoV-2 microneutralization assays with an area under the ROC curve of 98%. Sera obtained from patients with seasonal 42 43 coronaviruses did not show neutralizing activity in the LFA. After a single mRNA 44 vaccine dose, 87% of previously infected individuals demonstrated high levels of 45 neutralizing antibodies. However, if individuals were not previously infected only 24% 46 demonstrated high levels of neutralizing antibodies after one vaccine dose. A second 47 dose boosted neutralizing antibody levels just 8% higher in previously infected 48 individuals, but over 63% higher in non-infected individuals. 49 **Conclusions:** A rapid, semi-quantitative, highly portable and inexpensive neutralizing 50 antibody test might be useful for monitoring rise and fall in vaccine-induced neutralizing 51 antibodies to COVID-19.

52

53 KEYWORDS

54 Neutralizing Antibodies, COVID-19, SARS-CoV-2, Lateral Flow Assay, RBD, ACE2

55 INTRODUCTION

56	Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes			
57	COVID-19 and originated in Wuhan, China in December 2019 [1-3]. Vaccines continue			
58	to be tested [4,5] with the goal of preventing COVID-19 via induction of neutralizing			
59	antibodies (NAbs) and anti-viral T cells. Vaccine trials show that RNA vaccines elicit			
60	protective immunity, but durability of natural and vaccine-induced immunity is not fully			
61	known [5]. Several groups reported that up to one-third of serum samples from			
62	individuals who recovered from COVID-19 do not neutralize SARS-CoV-2 [6-8].			
63	Whether previously infected or vaccinated, it is informative for individuals to learn if they			
64	generated high levels of NAbs so that they can resume normal activities without fear of			
65	re-infection and transmitting the virus [9–11].			
66	Viral neutralization assays measure antibodies that block infection of host cells.			
67	The gold standard of neutralization for SARS-CoV-2 measures reduction of viral			
68	plaques or foci in microneutralization assays. These assays are slow, laborious, require			
69	highly trained personnel and a BSL3 facility. Another challenge is that neutralization			
70	assays require careful titration of virus and depend on host cells for infection, both of			
71	which add variability to the assay. These limitations prevent use of SARS-CoV-2			
72	neutralization assays for clinical applications.			
73	SARS-CoV-2 uses receptor binding domain (RBD) on spike protein to bind			
74	angiotensin converting enzyme 2 (ACE2) on host cells; RBD appears to be the principal			
75	neutralizing domain [12,13]. Using this knowledge, we developed a lateral flow assay			
76	(LFA) that measures levels of NAbs which block RBD from binding to ACE2. Other			
77	groups have developed RBD-ACE2-based competition ELISAs[18,19] but none have			

78	developed a rapid, highly portable, semi-quantitative test that can easily be incorporated
79	into clinical settings or research studies where traditional laboratory or neutralization
80	tests are not practical.
81	
82	MATERIALS AND METHODS
83	Human Subjects and Samples
84	Serum and finger-stick blood samples were collected for this study under an
85	Arizona State University institutional review board (IRB)-approved protocol
86	#0601000548 and Mayo Clinic IRB protocol #20-004544. Serum samples obtained
87	from excess clinical samples at Mayo Clinic were left over from normal workflow.
88	COVID-19 samples ranged from 3 to 84 days post PCR positive result.
89	Twenty-seven control serum samples from patients with non-COVID-19
90	respiratory illnesses as determined by the FilmArray Respiratory Panel 2 (Biofire
91	Diagnostics) were collected from patients from 2/14/17 – 4/6/20 as part of routine
92	clinical workflow. All residual clinical samples were stored at 2-8°C for up to 7 days, and
93	frozen at -80°C thereafter.

94

95 SARS-CoV-2 Microneutralization Assay

A microneutralization assay was performed using a recombinant SARS-CoV-2 expressing mNeonGreen (SARS-CoV-2ng) as previously described [16]. Inhibitory concentrations for which 50% of virus is neutralized by serum antibodies (IC₅₀ values) were obtained on a set of 38 COVID-19 sera. Sixty μ I aliquots of SARS-CoV-2ng were pre-incubated for 1 h in 5% CO₂ at 37°C with 60 μ I 2-fold serum dilutions in cell culture

101	media, and 100µl were inoculated onto Vero-E6 monolayers in black polystyrene 96-
102	well plates with clear bottoms (Corning) in duplicate. The final amount of the virus was
103	200 PFU/well, the starting serum dilution was 1:20 and the end dilution was 1:1280
104	unless an IC_{50} was not reached in which case serum was diluted to 1:10240. Cells were
105	maintained in Minimal Essential Medium (ThermoFisher Scientific) supplemented by 2%
106	FBS (HyClone) and 0.1% gentamycin in 5% CO_2 at 37°C. After 2 days of incubation,
107	fluorescence intensity of infected cells was measured at 488 nm using a Synergy 2 Cell
108	Imaging Reader (Biotek). Signal was normalized to virus alone with no serum added
109	and reported as percent neutralization. IC_{50} was calculated with GraphPad Prism 6.0
110	software. Work was performed in a BSL-3 biocontainment laboratory of the University of
111	Texas Medical Branch, Galveston, TX.

112

113 Serologic Antibody Assay

The Ortho Vitros Anti-SARS-CoV-2 IgG test (Ortho Vitros test) was performed on an Ortho Clinical Diagnostics Vitros 3600 Immunodiagnostics System at the Mayo Clinic. This assay is approved for clinical testing under FDA Emergency Use Authorization to qualitatively detect antibody to the S1 subunit of SARS-CoV-2 spike protein. Results are reported as reactive (S/CO \ge 1.0) or nonreactive (S/CO <1.0). Specimens were tested within 7 days of collection and stored at 2-8°C. The same 38 serum samples were run in the Ortho Vitros test, microneutralization assay, and the LFA.

121

122

123 Lateral Flow Neutralizing Antibody Assay

124 The Lateral Flow NAb assay was developed to measure levels of antibodies that 125 compete with ACE2 for binding to RBD. The LFA single port cassette (Empowered 126 Diagnostics) contains a test strip composed of a sample pad, blood filter, conjugate pad, 127 nitrocellulose membrane striped with test and control lines, and an absorbent pad (Axim 128 Biotechnologies Inc). The LFA also contains a control mouse antibody conjugated to 129 red gold nanospheres and corresponding anti-mouse IgG striped at the control line. 130 LFAs were run at room temperature on a flat surface for 10 minutes prior to 131 reading results. To perform the test, 6.7µl of serum or 10µl whole blood were added to 132 the sample port followed by 60µl of chase buffer. After 10 minutes, densities of both test 133 and control lines were recorded in an iDetekt RDS-2500 density reader. 134 The test leverages the interaction between RBD-conjugated green-gold 135 nanoshells (Nanocomposix) that bind ACE2 at the test line when RBD-neutralizing 136 antibodies (RBD-NAbs) are absent or low. Test line density is inversely proportional to 137 RBD-NAbs present within the sample. As a semi-guantitative test, the results of the LFA 138 can be interpreted using a scorecard or a densitometer. A red line across from the "C" 139 indicates that the test ran properly. An absent or faint test line indicates high levels of 140 RBD-NAbs, whereas a dark test line suggests low or lack of RBD-NAbs. 141

Precision testing was performed using sera from one highly, and one nonneutralizing donor in replicates of 10. Density values were recorded as above and %CVs calculated using the formula: (Standard Deviation/Mean) * 100%.

145


146 Data Analysis

Pearson's correlation (r) was conducted to assess the strength and significance 147 148 of associations between the LFA, the Ortho Vitros test and IC₅₀ values. Regression 149 analysis using IC₅₀ values evaluated consistency [14] while Bland-Altman plots 150 assessed agreement and bias [17,18]. Correlation analysis was conducted using IBM 151 SPSS. For two-group analysis, IC_{50} values corresponding to >240 were categorized as 152 titer of \geq 1:320 (neutralizing), whereas IC₅₀ values \leq 240 were categorized as \leq 1:160 153 (low/non-neutralizing). Receiver operating characteristic (ROC) analysis was performed 154 to assess accuracy, sensitivity, and specificity of the LFA and Ortho Vitros tests in 155 assessing neutralization; optimal cutoffs for each method were established to maximize 156 area under curve (AUC) [19,20]. ROC analysis was conducted using R language in the 157 RStudio environment (version 3.6.2; RStudio PBC). All analyses were conducted using 158 raw values; data were not normalized, transformed, or scaled.

159


160 RESULTS

As shown at the bottom in **Figure 1A**, serum containing high levels of NAbs results in a weak or ghost test line because NAbs bind RBD on green-gold beads, preventing RBD from binding to the ACE2 receptor at the test line. Serum with low levels of NAbs results in a strong test line because little to no antibodies prevent RBD on beads from binding to ACE2. **Figure 1B** demonstrates results of the test using COVID-19 sera with different levels of NAbs.



- **Figure 1.** (A) Schematic of Neutralization LFA. Below each graphic is a representative
- 169 image of a lateral flow strip demonstrating actual line density. Addition of non-
- 170 COVID19-immune serum or plasma (top) does not block binding of RBD-beads (green
- 171 particles) to ACE2 resulting in the RBD-bead–ACE2 complex creating a visible line.

172 Addition of patient serum with moderate titer NAbs to the sample pad creates a weak 173 line (*middle*). Addition of patient serum with high titer NAbs (> 1:640) blocks binding of 174 RBD-beads to ACE2 such that no line is observed at the test location on the strip 175 (bottom). Red control line represents capture of a mouse monoclonal antibody coupled 176 to red beads. (B) Scorecard for measuring levels of NAbs. Red control line across from 177 the "C" on the cassette indicates that the test ran properly and the green test line across 178 from the "T" can be used to measure the ability of plasma or serum to block RBD on 179 gold nanoshells from binding to ACE2. (0) represents patient serum producing a visually 180 non-existent line with density units of 10,095 and an IC_{50} >500 (IC_{50} =1151); (1) 181 represents patient serum with a line density of 132,503 and an IC_{50} of 396; (2) 182 represents patient serum with a line density of 317,156 and an IC_{50} of 243; (3) 183 represents patient serum with a line density of 645,040 and an IC_{50} of 96. 184 185 To support the application of the LFA to measure NAb levels to SARS-CoV-2, we 186 tested 38 serum samples that were assigned IC₅₀ values in a SARS-CoV-2 187 microneutralization assay [16]. The experiment was performed in a blinded manner 188 such that personnel running either the LFA or the microneutralization assay did not 189 know the results of the comparator test. When line densities from the LFA were plotted 190 against IC₅₀ values determined in the microneutralization assay, serum samples with 191 strong neutralization activity demonstrated low line densities; this indicates that NAbs 192 inhibited RBD from binding to ACE2 (Figure 2).




193

194Figure 2. Comparison of RBD-ACE2 competition LFA density values with IC_{50} values195determined in a SARS-CoV-2 microneutralization assay on 38 samples (collected 3 to19690 days after PCR positive result). Ranges of IC_{50} values are shown on the X-axis197plotted against LFA line density units on the Y-axis.


198


199

200 Next, we determined if the LFA detected neutralization activity in serum samples 201 collected from patients with other PCR-confirmed respiratory viruses including seasonal 202 coronaviruses (**Figure 3A**) and for serum samples collected prior to December 2019 203 (**Figure 3B**). Neither seasonal respiratory virus sera, nor pre-December 2019 samples 204 showed neutralizing activity.




Sera from seasonal respiratory virus infections





We then compared both the Ortho Vitros test and our LFA to sera with IC_{50} values determined in the SARS-CoV-2 microneutralization assay using 38 COVID-19 sera. To assess agreement between our LFA and the Ortho Vitros test, density units from the LFA and values from the Ortho test were regressed onto IC_{50} values (**Supplemental Figure S1**).

- 220
- 221



Supplemental Figure S1. Regression analysis between (A) Ortho Vitros SARS-CoV-2 IgG test and (B) LFA and titer. Regression plots show explained variance (R^2) between compared methods. Thirty-eight samples were tested.


226

LFA values accounted for roughly 52% of observed variance in IC₅₀ values, while the Ortho Vitros test accounted for approximately 27% of IC₅₀ variance. LFA showed significant negative correlation with IC₅₀ values (r = -0.720, p < 0.001), while the Ortho Vitros test values showed a significant positive correlation to IC₅₀ values (r = 0.522, p =0.001). Additionally, the LFA and Ortho Vitros test values correlated with each other (r =-0.572, p < 0.001).

233 To evaluate bias, mean differences and 95% confidence intervals (CIs) were 234 calculated and plotted alongside limits of agreement (**Figure 4**). Both LFA and Ortho

Vitros test values showed strong agreement with titer, although the Ortho Vitros test showed a tendency to underestimate neutralizing capacity while the LFA method showed no bias.

238



239

Figure 4. Bland-Altman plots showing bias (mean difference and 95% Cl) and computed limits of agreement (mean difference \pm 2SD) between (A) Ortho Vitros Anti-SARS-CoV-2 IgG test and IC₅₀ values and (B) our LFA and IC₅₀ values. Thirty-eight samples were tested.

244


245

ROC analysis was performed to assess the ability of the LFA and the Ortho Vitros test to classify low/non-neutralizing (Neg, <1:160), and highly neutralizing groups (\geq 1:320) (**Figure 5**). As shown in **Figure 5B** and **5D**, the LFA misclassified one nonneutralizing sample (Neg, <1:160) as neutralizing (\geq 1:320) which the Ortho Vitros test also misclassified as neutralizing. The Ortho test also incorrectly classified five additional neutralizing samples as non-neutralizing.

Our LFA showed high accuracy for classification of neutralizing samples (AUC = 0.978), while the Ortho Vitros test showed modest accuracy (AUC = 0.856). Notably, while both methods showed roughly 90% sensitivity, the Ortho Vitros test showed only

255 70% specificity. In contrast, the LFA showed perfect specificity (100%) in this analysis of256 38 samples.

257 Optimal cutoffs were computed to maximize AUC. For the LFA, density unit 258 values below 263,000 classify samples as neutralizing and correspond to titers \geq 1:320. 259 Density values above this LFA cutoff classify samples in the non-neutralizing group. For 260 the Ortho Vitros test, values between 0 and 23.3 were representative of non-neutralizing 261 capacity, whereas values above 23.3 were reflective of the neutralizing group.



263	Figure 5. (A) Univariate ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG test for
264	discrimination of neutralizing samples (≥1:320) [AUC: 0.856, 95% CI: 0.697—0.953,
265	sensitivity = 0.9, specificity = 0.7]. (B) Box plot of Ortho Vitros Anti-SARS-CoV-2 IgG
266	test values between neutralizing (\geq 1:320) and non-neutralizing (Neg—1:160) groups. (C)
267	Univariate ROC analysis of LFA for discrimination of neutralizing samples (≥1:320)
268	[AUC: 0.978, 95% CI: 0.908—1.0, sensitivity = 0.9, specificity = 1.0]. (D) Box plot of LFA
269	values between neutralizing (≥1:320) and non-neutralizing (Neg—1:160) groups.
270 271	Precision studies were performed on replicate samples ($n=10$) and showed a CV

of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum

- sample from the low neutralizing range (Supplemental Table 1).
- 274


Low Neutralizing Range			
10 min	с	т	T/C Ratio at 10 min
1	503764	932173	1.850416068
2	484316	944154	1.949458618
3	509424	902070	1.770764628
4	441318	840951	1.905544301
5	484558	990076	2.043255916
6	472319	906922	1.920147189
7	519936	971429	1.868362645
8	495254	992223	2.00346287
9	467545	816303	1.745934616
10	534262	941643	1.762511652
Average	491269.6	923794.4	1.88198585
STD Dev	25849.98843	55966.17114	0.096780674
%CV	5.26	6.06	5.14

High Neutralizing Range			
10 min	с	т	T/C Ratio at 10 min
1	415421	232022	0.558522559
2	404845	286183	0.706895232
3	419873	261146	0.621964261
4	417475	248141	0.594385293
5	409970	263808	0.64348123
6	397812	294120	0.739344213
7	409681	237096	0.578733209
8	412275	242082	0.587185738
9	373751	222959	0.596544223
10	373339	224335	0.600888201
Average	403444.2	251189.2	0.622794416
STD Dev	16097.74032	23457.01668	0.055137744
%CV	3.99	9.34	8.85

275

276 **Supplemental Table 1.** Precision study using one Low Neutralizing Range serum 277 sample and one High Neutralizing Range serum sample in replicates of ten. Low range 278 neutralization is defined as densities from 370,000 – 800,000. The used for precision 279 analysis was from an individual who recovered from COVID-19 but did not neutralize 280 virus in the microneutralization assay ($IC_{50} < 20$). High neutralization range samples are 281 defined as densities from 10,000 – 369,999. This sample has an IC50 of 248. 282 283 Precision studies were performed on replicate samples (n=10) and showed a CV 284 of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum 285 sample from the low neutralizing range (Supplemental Table 1).

286 287	Since NAb levels may be considered correlates of protection, we tested sera
288	from RNA vaccine recipients (mRNA-1723 and BNT162b2) in "previously infected" and
289	"not previously infected" individuals using finger-stick blood in the rapid LFA (Figure 6).
290	In previously infected individuals at baseline (within 3 months of PCR-based diagnosis),
291	38% demonstrated high levels of NAbs. After the first vaccine dose, 87% of previously
292	infected individuals demonstrated high NAb levels, while only 24% of not previously
293	infected individuals developed high levels of NAbs. After the second vaccine dose,
294	levels of NAbs increased to 95% in the previously infected cohort, while NAb levels
295	increased to 87% in the not previously infected cohort. This data suggests that a
296	second vaccine dose is important for highest levels of NAbs.



297

299 Figure 6. NAb levels in prior infection and vaccine-induced individuals. (A)

Baseline indicates within one week of first vaccine dose; Post-1st Dose indicates withing one week of 2nd vaccine dose; Post 2nd Dose indicates 10-20 days after 2nd vaccine dose. High and Low indicates density ranges of Test lines shown in (B). Densities were read in a reader as described in Methods. Serum titers that correspond to high range densities are >1:1280 to ≥1:160. Serum titers corresponding to low range densities are <1:160.

306

307 DISCUSSION

308 We developed a rapid test that measures levels of NAbs in serum and whole 309 blood. As shown in Figure 2, the LFA correlates well with serologic titers determined 310 using a SARS-CoV-2 microneutralization assay, especially when serum sample IC_{50} 311 values are >250. Advantages of the LFA test are that it can be inexpensively and 312 rapidly deployed to determine levels of NAbs in vaccine recipients. Moreover, the test 313 can be used longitudinally to evaluate duration of protective immunity in naturally 314 infected and vaccinated individuals-many more than could ever be evaluated using 315 BSL2 or BSL3-based neutralization assays.

316

The LFA and Ortho Vitros test showed a significant correlation with each other (r= -0.572, p < 0.001), displaying good linear relation (r = -0.720, p < 0.001)[21]. The LFA accounts for 52% of observed IC₅₀ variance ($R^2 = 0.5187$), while the Ortho Vitros test accounts for 27% ($R^2 = 0.2725$). Although absolute quantitation demands an excellent coefficient of determination ($R^2 \ge 0.99$)[22], variables with $R^2 \ge 0.5$ are highly predictive in univariate regression models while measures with $R^2 < 0.5$ are recommended for use in multivariate models with complementary measures to increase predictive accuracy 324 [23,24]. Bland-Altman analysis (**Figure 4**) showed the Ortho Vitros test to be prone to 325 underestimation of IC_{50} values, while the LFA method did not exhibit over- or 326 underestimation bias. Furthermore, across mean values for both methods, the LFA 327 showed discrete differential values while the Ortho Vitros test struggled to differentiate 328 high neutralizing samples.

329

330 Using our rapid test to measure NAbs in previously infected vaccine recipients 331 and those who were not infected agrees with other studies in BSL3 facilities using 332 serum from venipuncture blood [5,25–29]. Natural infection may not elicit high levels of 333 NAbs [6-8], but a first dose of vaccine induces high levels of NAbs in the majority of 334 recipients similar to 2 doses of vaccine in non-previously infected individuals, 335 suggesting natural infection primes the immune system[30]. In naïve individuals, a 336 single dose of vaccine elicits high NAb levels (Titers >1:160) in only 24% of vaccine 337 recipients, leaving 76% of vaccine recipients with titers lower than 1:160 which would 338 not qualify for convalescent plasma donation according to FDA memo of March 9,2021. 339 After a second vaccine dose, the LFA indicated high levels of NAbs in 87% of recipients, 340 identical to levels observed in previously infected individuals after the first vaccine dose. These findings might suggest that a booster (3rd vaccine dose) in non-infected 341 342 individuals could induce the highest levels of NAbs in the most people. 343 344 Limitations of the LFA are that it uses only the RBD portion of spike protein. 345 Although the vast majority of reports indicate that the principle neutralizing domain is the

346 RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by

binding to the N-terminal domain of spike protein [31,32]. Also, since the spike protein 347 348 assumes multiple conformations during viral binding and entry [33], neutralizing 349 epitopes exist on the guaternary structure of spike [32]. Although RBDs on the 350 nanoparticles may associate, it is not known if they assume a native conformation. 351 Other limitations are the binary nature of this data analysis (high and low 352 neutralizing) of a continuous assay. NAb levels should be evaluated longitudinally to 353 assess rise and fall in NAb levels; this rapid test is well-suited for that role. Another 354 limitation is that the LFA does not differentiate high affinity anti-RBD NAbs from an 355 abundance of lower affinity anti-RBD NAbs. 356 This test may prove useful in monitoring COVID-19 vaccine recipients as a 357 correlate of protection. It would be logistically difficult to obtain a tube of blood from 358 every vaccine recipient for BSL3 work. However, since this LFA requires only a drop of 359 blood, individual use of this test might lead to more comprehensive longitudinal 360 monitoring of protective humoral immunity and indicate when boosters might be 361 required. 362 363 364 AUTHOR CONTRIBUTIONS 365 DL, SS and AS-N developed the LFA. AJ performed the experiments and interpreted 366 the results. PJ performed statistical analysis. EK, TG and KM contributed samples. 367 CK, AJ and KP tested vaccine recipients and interpreted results. SP, NK and AB 368 performed SARS-CoV-2 microneutralization assays and interpreted results LW and JM

369 contributed samples for preliminary experiments. MM-G designed the strip layout and

370 produced the strips for the vaccine study.

37	1
----	---

- 372 CONFLICTS OF INTEREST STATEMENT
- 373 DL and SS are co-founders of Sapphire, the research division of Axim Biotech. SS, MM-
- 374 G and AS-N are employees of Axim Biotech. Other authors have no conflicts regarding
- this work.
- 376
- 377 FUNDING
- 378 This study was funded in part by Axim Biotech, San Diego, CA
- 379

380 References

- 381 [1] I. Ghinai, T.D. McPherson, J.C. Hunter, H.L. Kirking, D. Christiansen, K. Joshi, R. Rubin, S. 382 Morales-Estrada, S.R. Black, M. Pacilli, M.J. Fricchione, R.K. Chugh, K.A. Walblay, N.S. 383 Ahmed, W.C. Stoecker, N.F. Hasan, D.P. Burdsall, H.E. Reese, M. Wallace, C. Wang, D. 384 Moeller, J. Korpics, S.A. Novosad, I. Benowitz, M.W. Jacobs, V.S. Dasari, M.T. Patel, J. 385 Kauerauf, E.M. Charles, N.O. Ezike, V. Chu, C.M. Midgley, M.A. Rolfes, S.I. Gerber, X. Lu, S. 386 Lindstrom, J.R. Verani, J.E. Layden, S. Brister, K. Goldesberry, S. Hoferka, D. Jovanov, D. 387 Nims, L. Saathoff-Huber, C. Hoskin Snelling, H. Adil, R. Ali, E. Andreychak, K. Bemis, M. Frias, 388 P. Quartey-Kumapley, K. Baskerville, E. Murphy, E. Murskyj, Z. Noffsinger, J. Vercillo, A. 389 Elliott, U.S. Onwuta, D. Burck, G. Abedi, R.M. Burke, R. Fagan, J. Farrar, A.M. Fry, A.J. Hall, 390 A. Haynes, C. Hoff, S. Kamili, M.E. Killerby, L. Kim, S.A. Kujawski, D.T. Kuhar, B. Lynch, L. 391 Malapati, M. Marlow, J.R. Murray, B. Rha, S.K.K. Sakthivel, S.E. Smith-Jeffcoat, E. Soda, L. 392 Wang, B.L. Whitaker, T.M. Uyeki, First known person-to-person transmission of severe 393 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA, The Lancet. 395 (2020) 1137-1144. https://doi.org/10.1016/S0140-6736(20)30607-3. 394
- [2] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu,
 J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R.
 Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel
 coronavirus in Wuhan, China, The Lancet. 395 (2020) 497–506.
- 399 https://doi.org/10.1016/S0140-6736(20)30183-5.
- 400 [3] R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented
 401 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2), Science.
 402 368 (2020) 489–493. https://doi.org/10.1126/science.abb3221.
- 403 [4] F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Pérez
 404 Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li,
 405 W.V. Kalina, D. Cooper, R.W. Frenck, L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal,

406 D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, W.C. Gruber, Safety and

- 407Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med. 383 (2020) 2603–2615.408https://doi.org/10.1056/NEJMoa2034577.
- 409 [5] A.T. Widge, N.G. Rouphael, L.A. Jackson, E.J. Anderson, P.C. Roberts, M. Makhene, J.D.
- 410 Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A.
- 411 Doria-Rose, S. O'Dell, S.D. Schmidt, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J.
- 412 Albert, K. Cross, V.-V. Edara, K. Floyd, M.S. Suthar, W. Buchanan, C.J. Luke, J.E.
- Ledgerwood, J.R. Mascola, B.S. Graham, J.H. Beigel, Durability of Responses after SARSCoV-2 mRNA-1273 Vaccination, N Engl J Med. (2020) 4.
- 415 [6] D.F. Robbiani, C. Gaebler, F. Muecksch, J.C.C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C.O.
- Barnes, A. Gazumyan, S. Finkin, T. Hagglof, T.Y. Oliveira, C. Viant, A. Hurley, H.-H.
 Hoffmann, K.G. Millard, R.G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S.T. Chen, V. Ramos,
- R. Patel, J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweger, L. Nogueira, M. Pack, J.
 Horowitz, F. Schmidt, Y. Weisblum, E. Michailidis, A.W. Ashbrook, E. Waltari, J.E. Pak, K.E.
 Huey-Tubman, N. Koranda, P.R. Hoffman, A.P. West, C.M. Rice, T. Hatziioannou, P.J.
 Bjorkman, P.D. Bieniasz, M. Caskey, M.C. Nussenzweig, Convergent Antibody Responses to
 SARS-CoV-2 Infection in Convalescent Individuals, Immunology, 2020.
- 423 https://doi.org/10.1101/2020.05.13.092619.
- J.A. Juno, H.-X. Tan, W.S. Lee, A. Reynaldi, H.G. Kelly, K. Wragg, R. Esterbauer, H.E. Kent, C.J.
 Batten, F.L. Mordant, N.A. Gherardin, P. Pymm, M.H. Dietrich, N.E. Scott, W.-H. Tham, D.I.
 Godfrey, K. Subbarao, M.P. Davenport, S.J. Kent, A.K. Wheatley, Immunogenic profile of
 SARS-CoV-2 spike in individuals recovered from COVID-19, Infectious Diseases (except
 HIV/AIDS), 2020. https://doi.org/10.1101/2020.05.17.20104869.
- [8] F. Wu, A. Wang, M. Liu, Q. Wang, J. Chen, S. Xia, Y. Ling, Y. Zhang, J. Xun, L. Lu, S. Jiang, H. Lu,
 Y. Wen, J. Huang, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
 patient cohort and their implications, MedRxiv Prepr. (2020) 20.
 https://doi.org/10.1101/2020.03.30.20047365.
- 433 [9] Z. Han, F. Battaglia, S.R. Terlecky, Discharged COVID-19 Patients Testing Positive Again for
 434 SARS-CoV-2 RNA: A Minireview of Published Studies from China, J. Med. Virol. (2020)
 435 jmv.26250. https://doi.org/10.1002/jmv.26250.
- 436 [10] G. Ye, Z. Pan, Y. Pan, Q. Deng, L. Chen, J. Li, Y. Li, X. Wang, Clinical characteristics of severe
 437 acute respiratory syndrome coronavirus 2 reactivation, J. Infect. 80 (2020) e14–e17.
 438 https://doi.org/10.1016/j.jinf.2020.03.001.
- 439 [11] V.T. Hoang, T.L. Dao, P. Gautret, Recurrence of positive SARS-CoV-2 in patients recovered
 440 from COVID-19, J. Med. Virol. (2020) jmv.26056. https://doi.org/10.1002/jmv.26056.
- [12] Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y. Yuen, Q.
 Wang, H. Zhou, J. Yan, J. Qi, Structural and Functional Basis of SARS-CoV-2 Entry by Using
 Human ACE2, Cell. (2020) S009286742030338X.
 https://doi.org/10.1016/j.cell.2020.03.045.
- [13] L. Premkumar, B. Segovia-Chumbez, R. Jadi, D.R. Martinez, R. Raut, A. Markmann, C.
 Cornaby, L. Bartelt, S. Weiss, Y. Park, C.E. Edwards, E. Weimer, E.M. Scherer, N. Rouphael,
 S. Edupuganti, D. Weiskopf, L.V. Tse, Y.J. Hou, D. Margolis, A. Sette, M.H. Collins, J. Schmitz,
- 448 R.S. Baric, A.M. de Silva, The receptor binding domain of the viral spike protein is an

1.10		
449		immunodominant and highly specific target of antibodies in SARS-CoV-2 patients, Sci.
450		Immunol. 5 (2020) eabc8413. https://doi.org/10.1126/sciimmunol.abc8413.
451	[14]	C.W. Tan, W.N. Chia, X. Qin, P. Liu, M.IC. Chen, C. Tiu, Z. Hu, V.CW. Chen, B.E. Young,
452		W.R. Sia, YJ. Tan, R. Foo, Y. Yi, D.C. Lye, D.E. Anderson, LF. Wang, A SARS-CoV-2
453		surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike
454		protein–protein interaction, Nat. Biotechnol. (2020). https://doi.org/10.1038/s41587-020-
455		0631-z.
456	[15]	Q.M. Hanson, K.M. Wilson, M. Shen, Z. Itkin, R.T. Eastman, P. Shinn, M.D. Hall, Targeting
457		ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug
458		repurposing screen of an AlphaLISA proximity assay, Biochemistry, 2020.
459		https://doi.org/10.1101/2020.06.16.154708.
460	[16]	X. Xie, A. Muruato, K.G. Lokugamage, K. Narayanan, X. Zhang, J. Zou, J. Liu, C. Schindewolf,
461	[=-]	N.E. Bopp, P.V. Aguilar, K.S. Plante, S.C. Weaver, S. Makino, J.W. LeDuc, V.D. Menachery,
462		PY. Shi, An Infectious cDNA Clone of SARS-CoV-2, Cell Host Microbe. 27 (2020) 841-
463		848.e3. https://doi.org/10.1016/j.chom.2020.04.004.
464	[17]	Davide Giavarina, Understanding Bland Altman analysis, Biochem. Medica. 25 (2015) 141–
465	[=/]	151. https://doi.org/10.11613/BM.2015.015.
466	[18]	N.Ö. Doğan, Bland-Altman analysis: A paradigm to understand correlation and agreement,
467		Turk. J. Emerg. Med. 18 (2018) 139–141. https://doi.org/10.1016/j.tjem.2018.09.001.
468	[19]	N.A. Obuchowski, J.A. Bullen, Receiver operating characteristic (ROC) curves: review of
469	[13]	methods with applications in diagnostic medicine, Phys Med Biol. (2018) 29.
470	[20]	C.T. Nakas, C.T. Yannoutsos, Ordered multiple-class ROC analysis with continuous
471	[20]	measurements, Med. Stat. 23 (November 30) 3437–49. https://doi.org/10.1002/sim.1917.
472	[21]	P. Schober, C. Boer, L.A. Schwarte, Correlation Coefficients: Appropriate Use and
473	נבדן	Interpretation, Anesth. Analg. 126 (2018) 1763–1768.
474		https://doi.org/10.1213/ANE.000000000002864.
475	[22]	J.D. Rights, S.K. Sterba, Quantifying explained variance in multilevel models: An integrative
476	[22]	framework for defining R-squared measures, Psychol. Methods. 24 (n.d.) 309–338.
477		https://doi.org/10.1037/met0000184.
478	[22]	J.D. Rights, S.K. Sterba, A framework of R-squared measures for single-level and multilevel
478	[25]	regression mixture models, Psychol. Methods. 23 (n.d.) 434–457.
479		https://doi.org/10.1037/met0000139.
480	[24]	J.D. Rights, S.K. Sterba, New Recommendations on the Use of R-Squared Differences in
	[24]	
482	[25]	Multilevel Model Comparisons, Multivar. Behav. Res. 55 (n.d.) 568–599.
483	[25]	L.A. Jackson, E.J. Anderson, N.G. Rouphael, P.C. Roberts, M. Makhene, R.N. Coler, M.P.
484		McCullough, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A. McDermott, B.
485		Flach, N.A. Doria-Rose, K.S. Corbett, K.M. Morabito, S. O'Dell, S.D. Schmidt, P.A. Swanson,
486		M. Padilla, J.R. Mascola, K.M. Neuzil, H. Bennett, W. Sun, E. Peters, M. Makowski, J. Albert,
487		K. Cross, W. Buchanan, R. Pikaart-Tautges, J.E. Ledgerwood, B.S. Graham, J.H. Beigel, An
488		mRNA Vaccine against SARS-CoV-2 — Preliminary Report, N. Engl. J. Med. 383 (2020)
489	[20]	1920–1931. https://doi.org/10.1056/NEJMoa2022483.
490	[26]	A. Lombardi, G. Bozzi, R. Ungaro, S. Villa, V. Castelli, D. Mangioni, A. Muscatello, A. Gori, A.
491		Bandera, Mini Review Immunological Consequences of Immunization With COVID-19

- 492 mRNA Vaccines: Preliminary Results, Front. Immunol. 12 (2021) 657711.
- 493 https://doi.org/10.3389/fimmu.2021.657711.
- 494 [27] U. Sahin, A. Muik, E. Derhovanessian, I. Vogler, L.M. Kranz, M. Vormehr, A. Baum, K. Pascal,
- J. Quandt, D. Maurus, S. Brachtendorf, V. Lörks, J. Sikorski, R. Hilker, D. Becker, A.-K. Eller, J.
 Grützner, C. Boesler, C. Rosenbaum, M.-C. Kühnle, U. Luxemburger, A. Kemmer-Brück, D.
- 497 Langer, M. Bexon, S. Bolte, K. Karikó, T. Palanche, B. Fischer, A. Schultz, P.-Y. Shi, C. Fontes-
- Garfias, J.L. Perez, K.A. Swanson, J. Loschko, I.L. Scully, M. Cutler, W. Kalina, C.A. Kyratsous,
 D. Cooper, P.R. Dormitzer, K.U. Jansen, Ö. Türeci, COVID-19 vaccine BNT162b1 elicits
- 500 human antibody and TH1 T cell responses, Nature. 586 (2020) 594–599.
- 501 https://doi.org/10.1038/s41586-020-2814-7.
- 502 [28] E.J. Anderson, N.G. Rouphael, A.T. Widge, L.A. Jackson, P.C. Roberts, M. Makhene, J.D.
 503 Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A.
 504 Doria-Rose, S. O'Dell, S.D. Schmidt, K.S. Corbett, P.A. Swanson, M. Padilla, K.M. Neuzil, H.
 505 Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V.V. Edara, K. Floyd, M.S. Suthar, D.R.
 506 Martinez, R. Baric, W. Buchanan, C.J. Luke, V.K. Phadke, C.A. Rostad, J.E. Ledgerwood, B.S.
 507 Graham, J.H. Beigel, Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in
 508 Older Adults, N. Engl. J. Med. 383 (2020) 2427–2438.
- 509 https://doi.org/10.1056/NEJMoa2028436.
- [29] N. Doria-Rose, M.S. Suthar, M. Makowski, S. O'Connell, A.B. McDermott, B. Flach, J.E.
 Ledgerwood, J.R. Mascola, B.S. Graham, B.C. Lin, S. O'Dell, S.D. Schmidt, A.T. Widge, V.-V.
 Edara, E.J. Anderson, L. Lai, K. Floyd, N.G. Rouphael, V. Zarnitsyna, P.C. Roberts, M.
 Makhene, W. Buchanan, C.J. Luke, J.H. Beigel, L.A. Jackson, K.M. Neuzil, H. Bennett, B. Leav,
 J. Albert, P. Kunwar, Antibody Persistence through 6 Months after the Second Dose of
 mRNA-1273 Vaccine for Covid-19, N. Engl. J. Med. (2021) NEJMc2103916.
 https://doi.org/10.1056/NEJMc2103916.
- 517 [30] J.E. Ebinger, J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J.C. Prostko, E.C. Frias, J.L. Stewart,
 518 J.E. Van Eyk, J.G. Braun, S. Cheng, K. Sobhani, Antibody responses to the BNT162b2 mRNA
 519 vaccine in individuals previously infected with SARS-CoV-2, Nat. Med. (2021).
 520 https://doi.org/10.1038/s41591-021-01325-6.
- [31] X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y. Yang, Z.
 Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J. Xu, C. Yu, J. Li, Q. Zhou,
 W. Chen, A neutralizing human antibody binds to the N-terminal domain of the Spike
 protein of SARS-CoV-2, Science. (2020) eabc6952.
- 525 https://doi.org/10.1126/science.abc6952.
- [32] L. Liu, P. Wang, M.S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J.F.-W. Chan, V. Sahi, A.
 Figueroa, X.V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P.D.
 Kwong, J.G. Sodroski, M.T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D.D. Ho, Potent neutralizing
 antibodies against multiple epitopes on SARS-CoV-2 spike, Nature. 584 (2020) 450–456.
 https://doi.org/10.1038/s41586-020-2571-7.
- [33] Y. Cai, J. Zhang, T. Xiao, H. Peng, S.M. Sterling, R.M. Walsh, S. Rawson, S. Rits-Volloch, B.
 Chen, Distinct conformational states of SARS-CoV-2 spike protein, Science. (2020)
 eabd4251. https://doi.org/10.1126/science.abd4251.
- 534
- 535